Sanofi-Aventis renews licenses for Genomatix chip analysis pipeline

September 27, 2007

Genomatix Software GmbH (Munich) announced today that Sanofi-Aventis has renewed its licenses for Multi-Site access to the Genomatix Microarray Analysis Pipeline.

The pipeline provides a fully integrated, user friendly solution for the analysis of expression and tiling microarray experiments, including the powerful ChIP on chip studies. Genomatix software module ChipInspector seamlessly integrates with additional modules (BiblioSphere PathwayEdition, ElDorado, Gene2Promoter, and GEMS Launcher) to achieve a molecular level understanding of how genes are regulated and co-regulated, providing the scientists at Sanofi-Aventis a comprehensive gene network and pathway analysis.

Martin Seifert, Vice President Microarray Business and Collaborative Research at Genomatix stated: "We are pleased that our existing relationship with Sanofi-Aventis has led to an extension of their existing licensing agreement. It confirms the validity of our integrated approach to understanding gene regulation by combining state of the art software, biological data bases, expert systems and scientific support, to provide a complete solution for the computational biologist."
-end-
Genomatix is a pioneer and leader in the analysis and understanding of eukaryotic gene regulation. Core competences at Genomatix are annotation driven microarray analysis, ChIP on chip, regulatory network and pathway mining, and promoter analysis on sequence level. Genomatix has published more than 170 peer reviewed scientific papers that have been cited in more than 4,000 papers. Over 35,000 researchers worldwide currently apply Genomatix tools and databases.

Genomatix Software GmbH

Related Gene Articles from Brightsurf:

NIH gene therapy startup to increase AAV gene therapy efficiency
Maximizing the efficiency of the adeno-associated virus (AAV) platform for gene therapy is the aim of a new pilot project of the National Institutes of Health (NIH).

Alzheimer's risk gene disrupts endocytosis, but another disease-linked gene could help
MIT researchers find that astrocytes with the risk-increasing APOE4 variant show deficits of key cellular function called endocytosis, but overexpressing another Alzheimer's associated gene, PICALM, overcame the defect

New Human Gene Therapy editorial: Concern following gene therapy adverse events
Response to the recent report of the deaths of two children receiving high doses of a gene therapy vector (AAV8) in a Phase I trial for X-linked myotubular myopathy (MTM).

Gene therapy/gene editing combo could offer hope for some genetic disorders
A hybrid approach that combines elements of gene therapy with gene editing converted an experimental model of a rare genetic disease into a milder form, significantly enhancing survival, shows a multi-institutional study led by the University of Pennsylvania and Children's National Hospital in Washington, D.C.

Unraveling gene expression
EPFL chemists have uncovered the first steps in the process of gene expression by showing how the protein Rap1 pries open the tightly wound, compacted structure of DNA in the cell to gain access to specific genes.

Gene coding error found in rare, inherited gene cof lung-scarring disorder linked to short telomeres
By combing through the entire genetic sequences of a person with a lung scarring disease and 13 of the person's relatives, Johns Hopkins Medicine researchers say they have found a coding error in a single gene that is likely responsible for a rare form of the disease and the abnormally short protective DNA caps on chromosomes long associated with it.

The two faces of the Jekyll gene
Genes which are specific to a species or group of species can reflect important genetic changes within lineages.

Gene therapy vectors carrying the telomerase gene do not increase the risk of cancer
Researchers from the Spanish National Cancer Research Centre (CNIO) have shown in a new study that the gene therapy with telomerase that they have developed, and which has proven to be effective in mice against diseases caused by excessive telomere shortening and ageing, does not cause cancer or increase the risk of developing it, even in a cancer-prone setting.

Blindness gene discovered
Researchers from UNIGE have investigated a recessive genetic disorder that destroys the eyes from developing and results in childhood blindness.

Gene editing just got easier
An international team of researchers has made CRISPR technology more accessible and standardized by simplifying its complex implementation in a way that offers a broad platform for off-the shelf genome engineering.

Read More: Gene News and Gene Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.